1. Generics Bulletin
  2. >>Partnered Content

Achieving Firsts In Biosimilars From China

 
• By Andrew Warmington

Explore this insightful article and exclusive video with Henlius’ COO to discover:

  • Its achievements in biosimilar approvals, including serplulimab, and its anticipated launch into the European market.
  • The essential role of strategic partnerships in Henlius’ success, including over 20 global collaborations with Abbott Laboratories, Accord Healthcare, Eurofarma and more.
  • An overview of Henlius’ late-stage pipeline drugs, and ambitious plans shaping the future of biosimilars.

Click here to download this Special Report in PDF format


More from Partnered Content

Sponsored by:

Making medicines more affordable to the NHS

Delve into the challenges facing the NHS, from rising medicine costs to supply shortages, and how generics and branded generics can provide solutions for a more sustainable healthcare system

In Partnership With

Achieving Firsts In Biosimilars From China

Discover Henlius’ groundbreaking achievements, and their mission to deliver affordable, innovative drugs worldwide through strategic partnerships.

More from Products

Sponsored by:

Making medicines more affordable to the NHS

Delve into the challenges facing the NHS, from rising medicine costs to supply shortages, and how generics and branded generics can provide solutions for a more sustainable healthcare system

Sponsored by:

Oncology R&D trends at a glance

Access key stats from biotechs on the latest trends impacting oncology R&D, including therapeutic pipelines and clinical trial challenges, AI/ML, and a future outlook on innovation.

Sponsored by:

Infographic: Advancing Drug Development in Oncology

Gain exclusive insights into the biggest challenges biotechs face in oncology and uncover the latest opportunities to accelerate drug development.

Sponsored by:

Japan’s Strengths As A Clinical Study Location And Why Selecting The Right Partner Is Crucial

Learn about the critical role the right CRO plays in successfully navigating the significant drug development opportunities in Japan.